Insights On CONTRACT PHARMA MANUFACTURING

  1. Global Manufacturing Excellence Across Quality, Efficiency, And Cost Of Goods Sold 3/26/2026

    Learn strategies to strengthen global biologics manufacturing through consistent quality, advanced technologies, and efficient tech transfer to improve operations and commercial readiness.

  2. Deciphering The Complexity Of Therapeutic Biologics 3/26/2026

    This session breaks down essential analytical approaches that strengthen biologics development, from defining critical quality attributes to supporting comparability and regulatory readiness. 

  3. Enhancing AAV Production Performance And Economics 3/24/2026

    Enzymatically produced dbDNA offers safer, faster, and more scalable AAV manufacturing by reducing costs, improving full capsid yields, and enabling high‑fidelity, bacteria‑free DNA production.

  4. Engineering The Next Wave Of CHO Performance 3/24/2026

    By combining improved productivity with speed and reliability, S-CHOice® 2G helps biopharmaceutical companies optimize their manufacturing strategies, reduce overall costs, and respond more effectively to market demands.

  5. Pace Life Sciences Capabilities Update March 2026: Analytical Services 3/24/2026

    A CDMO leader highlights two decades of growth, showcasing analytical strength, manufacturing, regulatory support, and integrated services that speed drug development.

  6. Solvias Capabilities Update March 2026: Analytical Services 3/24/2026

    A biotech leader highlights end‑to‑end analytical capabilities from development to commercialization, with expertise in biologics, gene therapies, quality testing, and regulatory solutions.

  7. Catalent Capabilities Update March 2026: Analytical Services 3/24/2026

    A biologics analytics leader showcases development, testing, and characterization capabilities, emphasizing quality, regulatory compliance, and integrated support from discovery to commercialization.

  8. Minaris Advanced Therapies Capabilities Update March 2026: Cell & Gene Therapy 3/24/2026

    A global CDMO specializing in cell and gene therapies, offering end-to-end development, manufacturing, and testing services with over 25 years of expertise and personalized client support.

  9. Lonza Capabilities Update March 2026: Cell & Gene Therapy 3/24/2026

    A global CDMO outlines end-to-end capabilities in cell and gene therapy, mRNA, and microbial platforms, emphasizing scalability, innovation, and seamless development through commercial manufacturing.

  10. Landmark Bio Capabilities Update March 2026: Cell & Gene Therapy 3/24/2026

    A translational CDMO approach integrates development, analytics, and GMP manufacturing to streamline cell and gene therapy advancement from early research through scalable clinical production.